Abstract:BACKGROUND: High-density lipoprotein (HDL) plays an antiatherogenic role by mediating reverse cholesterol transport (RCT), antioxidation, anti-inflammation, and endothelial cell protection. Recently, series of evidence have shown that HDL can also convert to proatherogenic HDL under certain circumstances. Plasma paraoxonase 1 (PON1) as an HDL-bound esterase, is responsible for most of the antioxidant properties of HDL. However, whether PON1 can serve as a therapeutic target of dysfunctional HDL-related atherosclerosis remains unclear.METHODS: In this study, scavenger receptor class B type I deficient (Scarb1-/- ) mice were used as the animal model with dysfunctional HDL and increased atherosclerotic susceptibility. Hepatic PON1 overexpression and secretion into circulation were achieved by lentivirus injection through the tail vein. We monitored plasma lipids levels and lipoprotein profiles in Scarb1-/- mice, and measured the levels and activities of proteins associated with HDL function. Meanwhile, lipid deposition in the liver and atherosclerotic lesions was quantified. Hepatic genes relevant to HDL metabolism and inflammation were analyzed.RESULTS: The results showed the relative levels of PON1 in liver and plasma were increased by 1.1-fold and 1.6-fold, respectively, and mean plasma PON1 activity was increased by 63%. High-level PON1 increased the antioxidative and anti-inflammatory properties, promoted HDL maturation and macrophage cholesterol efflux through increasing HDL functional proteins components apolipoprotein A1 (APOA1), apolipoprotein E (APOE), and lecithin-cholesterol acyltransferase (LCAT), while decreased inflammatory protein markers, such as serum amyloid A (SAA), apolipoprotein A4 (APOA4) and alpha 1 antitrypsin (A1AT). Furthermore, hepatic PON1 overexpression linked the effects of antioxidation and anti-inflammation with HDL metabolism regulation mainly through up-regulating liver X receptor alpha (LXRα) and its downstream genes. The pleiotropic effects involved promoting HDL biogenesis by raising the level of APOA1, increasing cholesterol uptake by the liver through the APOE-low density lipoprotein receptor (LDLR) pathway, and increasing cholesterol excretion into the bile, thereby reducing hepatic steatosis and aorta atherosclerosis in Western diet-fed mice.CONCLUSIONS: Our study reveals that high-level PON1 improved dysfunctional HDL and alleviated the development of atherosclerosis in Scarb1-/- mice. It is suggested that PON1 represents a promising target of HDL-based therapeutic strategy for HDL-related atherosclerotic cardiovascular disease.

Probucol Up-Regulates Paraoxonase 1 Expression in Hepatocytes of Hypercholesterolemic Rabbits

Probucol alleviates atherosclerosis and improves high density lipoprotein function

Effect of probucol on HDL metabolism and class B type I scavenger receptor (SR-BI) expression in the liver of hypercholesterolemic rabbits.

Paraoxonase 1 interactions with atherosclerotic lesions and arterial macrophages protect against foam cell formation and atherosclerosis development

Probucol Inhibits Atherosclerosis by Regulating ABCA1, SR-B I, ABCG5 and ABCG8 Expression and Anti-inflammatory Effects in Hypercholesterolemic Rabbits

Effect of the Anti-Oxidant Probucol on Soluble Thrombomodulin (stm) in Hypercholesterolemic Rabbits

Effect of Probucol on Enzyme and Receptors of High Density Lipoprotein During Reverse Cholesterol Transportation in Experimental Rabbits With Atherosclerosis

Probucol Protects Against Atherosclerosis Through Induction of Heme Oxygenase-1

Paradoxical enhancement of atherosclerosis by probucol treatment in apolipoprotein E-deficient mice.

Abstract 288: Atheroprotective Effect of Probucol is Related to Its Heme Oxygenase 1 Activation and Subsequent Suppression of Oxidized Low-Density Lipoprotein--Induced Dendritic Cell Maturation

Probucol Protects Endothelial Progenitor Cells Against Oxidized Low-Density Lipoprotein via Suppression of Reactive Oxygen Species Formation In Vivo.

The effect and mechanism of probucol on HDL function in atherosclerotic rabbits

Hepatic paraoxonase 1 ameliorates dysfunctional high-density lipoprotein and atherosclerosis in scavenger receptor class B type I deficient mice

Probucol and Cilostazol Exert a Combinatorial Anti-Atherogenic Effect in Cholesterol-Fed Rabbits

Combined Effects of Pravastatin and Probucol on High-Density Lipoprotein Apolipoprotein A-I Kinetics in Cholesterol-fed Rabbits.

Probucol reduces myeloperoxidase expression in peripheral blood monocytes from patients with acute coronary syndrome

Probucol Protects Against Atherosclerosis Through Lipid-lowering and Suppressing Immune Maturation of CD11c+ Dendritic Cells in STZ-induced Diabetic LDLR−/− Mice

Abstract P298: Probucol Inhibits Oxidized Low-Density Lipoprotein--Induced Immune Maturation of Dendritic Cells Via Heme Oxygenase 1

Effects of probucol on hepatic tumor necrosis factor-α, interleukin-6 and adiponectin receptor-2 expression in diabetic rats

Comparison of the effects of alpha-tocopherol, ubiquinone-10 and probucol at therapeutic doses on atherosclerosis in WHHL rabbits

Effect of Organophosphorus Insecticide to Aggravate Hyperlipidemic Diet Inducing Atherosclerosis Ralated to Decrease of Paraoxonase Activity in Rabbits